Bebtelovimab no longer authorized in the United States. On Nov. 30, 2022, U.S. Food and Drug Administration (FDA) revoked its Emergency Use Authorization (EUA) for bebtelovimab. Bebtelovimab is a monoclonal antibody used to treat COVID-19. FDA revoked the EUA because the drug lost efficacy against most SARS-CoV-2 variants currently circulating in the United States. Currently, … 12/12/22 Health Advisory: COVID-19 Therapeutics Updates
On Nov. 18, Washington State Department of Health (DOH) issued a high-level alert on a surge in respiratory syncytial virus (RSV) causing remarkable strain on pediatric emergency departments (EDs) and intensive care units (ICUs). This alert followed Centers for Disease Control and Prevention’s (CDC’s) Nov. 4 Health Alert Network (HAN) advisory on multiple viruses causing … 11/22/22 Health Advisory: Pediatric respiratory illness increasing in Western Washington
Multiple viruses are causing increased respiratory illness, especially among children, straining healthcare systems. Transmission of respiratory illnesses is increased in our communities. Schools report much higher absenteeism than normal for this time of year. Our hospital emergency departments are seeing many patients. This increase in illness early in respiratory illness season highlights the importance of … 11/08/22 Health Advisory: Increased Respiratory Virus Activity
Requested actions Vaccine This season’s updates in Centers for Disease Control and Prevention’s (CDC’s) Prevention and Control of Influenza (MMWR Vol. 71/No. 1): Surveillance Seasonal influenza surveillance starts in October and continues through April. We expect SARS-CoV-2 and influenza viruses will circulate simultaneously. To aid testing and treatment decisions, stay aware of local influenza and … 10/27/22 Health Advisory: 2022–2023 Influenza Season Surveillance, Testing & Treatment
Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA) and Western States Scientific Safety Review Workgroup approved an age expansion for updated bivalent COVID-19 vaccine booster doses. The expansion allows children: 5–11 years old to get 1 booster dose of Pfizer pediatric updated bivalent COVID-19 vaccine. 6–17 years old to get 1 … 10/19/22 Health Advisory: Updated bivalent COVID-19 boosters available to children 5 years or older
Since May 2022, the United States has seen more than 25,000 cases of monkeypox virus (MPV). Most cases are mild to moderate, but some people are at higher risk of severe illness: Under 8 years old. Immune compromise. Atopic dermatitis or eczema. Pregnant. Unsuppressed or uncontrolled human immunodeficiency virus (HIV). Of those currently diagnosed with MPV … 10/03/22 Health Advisory: Severe cases of monkeypox among people with immune compromise
COVID-19 Monkeypox Monkeypox virus (MPV) is an ongoing health emergency. Pierce County has 40 reported cases. The United States has over 21,000 reported cases. See our provider resources monkeypox page for prevention, testing and treatment guidance. Monkeypox is a notifiable condition. Call to report suspected or confirmed cases within 24 hours. Jynneos vaccine We have a limited … 09/09/22 Health Advisory: COVID-19 and Monkeypox Update for Providers
Requested actions Be aware: Moderna and Pfizer created bivalent formulations of their mRNA COVID-19 vaccines. The bivalent vaccines target the original strain of SARS-CoV-2 and Omicron subvariants BA.4 and BA.5. United States Food and Drug Administration (FDA) granted emergency use authorization (EUA) to the bivalent vaccines for use as a single booster dose. People can get … 09/02/22 Health Advisory: Bivalent Vaccine Booster for COVID-19
Requested actions Suspect monkeypox virus (MPV) infection in any patient who presents with 1 or more lesions that suggest MPV, regardless of the patient’s age, social history, gender or sexual identity. Several commercial labs, as well as Washington State Public Health Labs (PHL), now test for MPV. PHL updated its MPV specimen collection guidance: Preferred … 08/25/22 Health Advisory: Monkeypox and COVID-19 Update for Providers
Requested actions Be aware, Novavax COVID-19 vaccine is now available to order. Food and Drug Administration (FDA) granted it emergency use authorization (EUA) and Centers for Disease Control and Prevention (CDC) and Western States Scientific Safety Review Workgroup approved. EUA covers a 2-dose primary series for people 18 years or older, including those with immune compromise. Booster … 07/28/22 Health Advisory: Novavax Available to Order
